首页> 外文期刊>Journal of health politics, policy and law >Reply to DiMasi, Hansen, and Grabowski.
【24h】

Reply to DiMasi, Hansen, and Grabowski.

机译:回复DiMasi,Hansen和Grabowski。

获取原文
获取原文并翻译 | 示例
           

摘要

Besides critiquing the Congressional Budget Office for failing to cite and discuss evidence from independent sources that suggest that the net corporate costs of pharmaceutical research and development costs are much lower than industry advocates claim, Light's review showed how these high estimates are constructed realities that one can reconstruct by using different assumptions, data, or calculations and come up with much lower estimates. In their reply here, DiMasi, Hansen, and Grabowski unwittingly reinforce that point.
机译:除批评美国国会预算办公室未能引用和讨论独立来源的证据表明制药研究与开发成本的公司净成本远低于行业倡导者的说法外,莱特的评论还显示了这些高估是如何构成的现实,通过使用不同的假设,数据或计算进行重构,并得出低得多的估算值。 DiMasi,Hansen和Grabowski在这里的答复在不经意间强化了这一点。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号